Open Dialogue versus treatment as usual for adults presenting in crisis to mental health services in England (the ODDESSI Trial): a multisite cluster-randomised trial.

Lancet PsychiatryAug 26, 2026 (epub)
Clinical ResearchPsychiatry

Stephen Pilling, Thomas Craig, Katherine Clarke et al.

✦ AI-curated · Sources linked

In 30 seconds

The ODDESSI Trial, a multicenter cluster-randomised trial, evaluated the effectiveness of Open Dialogue versus treatment as usual for adults in crisis within mental health services in England. Among 494 participants, there was no significant difference in time to relapse after recovery (marginal hazard ratio 0.95). However, Open Dialogue showed lower rates of psychiatric admissions and improved self-rated recovery and satisfaction.

Key findings

  • No significant difference in time to relapse between Open Dialogue and treatment as usual (marginal hazard ratio 0.95).
  • Open Dialogue was associated with lower probabilities of psychiatric inpatient admission.
  • Participants in Open Dialogue reported better health-related quality of life and satisfaction with services.

Why it matters

This study highlights the potential benefits of Open Dialogue in reducing hospital admissions and improving patient-reported outcomes, suggesting a need for further exploration of person-centered approaches in mental health care.

Source

PubMed · PMID 42648300

Published in Lancet Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.